articleThe LancetMay 4, 2017GREEN OA

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

ABAndrew BlauveltMDMarjolein de Bruin‐WellerMGMelinda GooderhamJCJennifer Clay CatherJWJamie Weisman

Oregon Medical Research Center · University Medical Center Utrecht · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,231
total citations
FWCI
119.44
Percentile
100%
References
47
Citations per year

Authors

31

Topics & keywords

Topics
Keywords
  • Dupilumab
  • Eczema Area and Severity Index
  • Atopic dermatitis
  • Medicine
  • Placebo
  • Concomitant
  • Clinical endpoint
  • Dermatology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding